Tag Archives: Warren Woessner

PTO “POINT SYSTEM” DISTRIBUTED

I thought it worthwhile to post this “point system,” since I had never seen one before. It is encouraging that the highest tier of points an Examiner can achieve is a first office action allowance, but a little discouraging that … Continue reading

Posted in USPTO Practice and Policy | Tagged , , , , | Leave a comment

Novelty and Obviousness In An Empirical Research Field – The Decision of the UK Court of Appeal in Dr Reddy’s Laboratories v Eli Lilly

From Paul Cole The Lilly patent for olanzapine has been litigated in many jurisdictions including the US, Canada, the Czech Republic, Finland, Levitra order online Romania, Slovakia, Slovenia, Spain, China and Hungary. In US Court of Appeals for the Federal … Continue reading

Posted in Non-U.S. Practice | Tagged , , , , , | Leave a comment

Neutrokine-α litigation – On a different record from that before the EPO Appeal Board, the UK Court of Appeal finds different facts with a different result

From Paul Cole of Lucas & Cole On February 9th the Court of Appeal ([2010] EWCA Civ 33; Jacob L.J.) held that Human Genome Sciences Patent EP-B-093 cheap cialis online 9804 for Neutrokine-α did not meet the industrial applicability requirement … Continue reading

Posted in Utility/How-To-Use | Tagged , , , , | Leave a comment

USPTO Request for Comments on Enhancement in the Quality of Patents

In the December 9, 2009 issue of the Fed. Reg., the PTO requested public comments on a wide range of patent preparation and prosecution topics, from “Finding the Best Prior Art” to issuing and responding to first office actions and … Continue reading

Posted in USPTO Practice and Policy | Tagged , | Leave a comment